Rxsight, Inc. Stock Price, News & Analysis

RxSight, Inc. (NASDAQ: RXST) has announced its participation in the J.P. Morgan Healthcare Conference, scheduled for January 11, 2023, at 11:15 a.m. PT. This event focuses on enhancing vision for cataract surgery patients through innovative technologies. RxSight's Light Adjustable Lens system is the first customizable intraocular lens technology aimed at optimizing post-surgery visual acuity. Interested parties can access the live and archived webcast via this link.

RxSight, Inc. reported Q3 2022 revenue of $12.6 million, marking a 118% increase year-over-year. Key drivers included 49 Light Delivery Devices sold, a 58% unit increase, and 6,595 Light Adjustable Lenses, up 234% in procedures. The company raised its full-year revenue guidance to $47.0 million - $48.0 million, indicating a growth of 108% - 112%. However, operational costs rose by 47.5%, leading to a net loss of $(16.8) million.

RxSight, Inc. (NASDAQ: RXST), an ophthalmic medical device company, will announce its third quarter 2022 financial results on November 7, 2022, after market close. Management will host a conference call at 1:30 p.m. PT to discuss the results. The company is known for its innovative RxSight Light Adjustable Lens system that allows customization of visual acuity post-cataract surgery. This advanced technology is the first of its kind in the intraocular lens market.

RxSight, Inc. (NASDAQ: RXST), a medical device company focused on enhancing vision post-cataract surgery, will participate in the Wells Fargo Healthcare Conference on September 8, 2022, at 8:35 a.m. PT / 11:35 a.m. ET. The event will feature a fireside chat with management, and interested parties can access a live and archived webcast through their investor relations website.

RxSight specializes in innovative lens technology, including the RxSight Light Adjustable Lens system, which allows doctors to tailor visual acuity for patients after cataract procedures.

RxSight, Inc. (NASDAQ: RXST) has filed a $200 million shelf registration statement with the SEC, allowing it to sell various securities including common and preferred stock. This strategy aims to provide flexibility in accessing capital under favorable market conditions. Specifically, the company also intends to offer up to $50 million of common stock through an at-the-market (ATM) offering, managed by BofA Securities. The registration is pending effectiveness, and the company emphasizes the importance of reviewing the prospectus for potential investment risks.

RxSight, Inc. reported significant financial growth for Q2 2022, with revenues of $11.4 million, marking a 132% increase year-over-year. The company's sales included 49 Light Delivery Devices (LDDs), a 96% increase, and 5,400 Light Adjustable Lenses (LALs), representing a 196% rise in procedures. Full-year revenue guidance is now set at $44.0 to $46.0 million, indicating a growth rate of 95% to 104% compared to 2021. Despite a net loss of $(16.7) million, the company is seeing robust demand for its products.

RxSight, Inc. (NASDAQ: RXST) will report its Q2 2022 financial results on August 8, 2022, after market close. A conference call is scheduled for 1:30 PM PT / 4:30 PM ET to discuss these results. Interested parties can access a live and archived webcast via the Investors page on RxSight's website. The company is focused on improving post-cataract surgery vision with its unique RxSight Light Adjustable Lens system, which includes advanced ActivShield technology. More details are available on their website.

RxSight, Inc. (NASDAQ: RXST) reported strong financial results for Q1 2022, achieving $8.9 million in revenue, a 157% increase from Q1 2021. Key drivers included a sale of 40 Light Delivery Devices (LDDs) and 4,166 Light Adjustable Lenses (LALs), marking growth of 208% and 166% in volume, respectively. Gross profit also surged to $3.7 million (42% of revenue). However, operating expenses rose 66% to $20.3 million, resulting in a net loss of $17.6 million. The company has revised its 2022 revenue guidance upward to $41.5 million to $45.5 million.

RxSight, a medical device company focused on ophthalmic solutions, will present at the Bank of America Healthcare Conference on May 10, 2022, at 12:00 PM PT. This event will showcase the company's innovative RxSight Light Adjustable Lens system, which allows for customized visual acuity post-cataract surgery. The system now includes ActivShield technology for added UV protection. A live and archived webcast of the presentation will be available on their website under the 'Investors' section.